Amended Statement of Changes in Beneficial Ownership (4/a)

FORM 4

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number:

3235-0287

Estimated average burden
hours per response...

0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Raleigh Jason Philip	2. Issuer Name and Ticker or Trading Symbol NovaBay Pharmaceuticals, Inc. [ NBY ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) Interim CFO and Treasurer
(Last)          (First)          (Middle) C/O NOVABAY PHARMACEUTICALS, INC., 2000 POWELL STREET, SUITE 1150	3. Date of Earliest Transaction (MM/DD/YYYY) 6/10/2019
(Street) EMERYVILLE, CA 94608 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY) 6/12/2019	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock (1)	6/10/2019		A		23405	A	$2.20	23405	D
Common Stock (1)	6/10/2019		S		23405	D	$3	0	D
Common Stock (1)	6/11/2019		A		9750	A	$2.35	9750	D
Common Stock (1)	6/11/2019		S		9750	D	$3.75	0	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.20	6/10/2019		X			23405	5/31/2019	5/31/2028	Common Stock	23405	$0	0	D
Stock Option (right to buy)	$2.35	6/11/2019		X			9750	6/2/2018	6/2/2027	Common Stock	9750	$0	0	D

Explanation of Responses:
(1)	The amended Form 4 is being filed to show (1) the corresponding acquisition of common stock after the exercise of options in Table I and (2) the immediate sale of common stock after such exercise of options in Table I.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Raleigh Jason Philip C/O NOVABAY PHARMACEUTICALS, INC. 2000 POWELL STREET, SUITE 1150 EMERYVILLE, CA 94608			Interim CFO and Treasurer

Signatures
/s/ Jason Philip Raleigh		10/28/2019
**Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

1 Year NovaBay Pharmaceuticals Chart

1 Month NovaBay Pharmaceuticals Chart